AstraZeneca
catalyst rich path through with potential to unlock significant value through and beyond indication expansion key opportunities disruptive technologies her cell therapy and phase i multiple bladder trials in house phase i and phase i calypso weight management phase i pipeline momentum supports ambition to achieve in total revenue by | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
25 of 38
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
BioAtla
Investor Presentation
May 2023
phase part | BioAtla
Exscientia
Investor Presentation
August 2023
why are our clinical candidates different | Exscientia
Norwegian Cruise Line
Results
May 2022
key full fleet back in service strong demand robust pricing for future cruises tremendous growth opportunity | Norwegian Cruise Line
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io